Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06624475 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma

Study acronym: NEON
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site contacts updated at 1 of 3 sitesv8
  2. Eligibility criteria expanded, about 14 words Site details revised at 2 of 3 sitesv7 Show 1 more changeShow less
    • Site details revised at 2 of 3 sites

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 1 to 3 Interventions: Nivolumab (Drug), Opdualag (Drug) to Nivolumab (Drug), Relatlimab plus Nivolumab (Drug) · Study description expanded, about 3 words · Study title expanded, about 3 wordsv6 Show 3 more changesShow less
    • Interventions: Nivolumab (Drug), Opdualag (Drug) to Nivolumab (Drug), Relatlimab plus Nivolumab (Drug)
    • Study description expanded, about 3 words
    • Study title expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Aug 2025 to Aug 21, 2025 · Site details revised · Collaborators expanded, about 2 wordsv5 Show 3 more changesShow less
    • Start date changed from estimate of Aug 2025 to Aug 21, 2025
    • Site details revised
    • Collaborators expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  5. Start date: May 2025 to Aug 2025v4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Jan 2025 to May 2025 Study sites: 0 to 1 · Primary and study completion dates: Feb 2028 to May 2028v3 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Primary and study completion dates: Feb 2028 to May 2028
  2. Start date: Oct 2024 to Jan 2025 Primary and study completion dates: Dec 2027 to Feb 2028v2 Show 1 more changeShow less
    • Primary and study completion dates: Dec 2027 to Feb 2028
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 2 clinical trial with a 2:1 randomization comparing neoadjuvant Nivolumab + Relatlimab (Opdualag) vs neoadjuvant Nivolumab in patients with resectable high risk basal cell carcinoma (HR BCC)
Trial Details
NCT Number NCT06624475
Lead Sponsor University of California, San Diego
Collaborators: Bristol-Myers Squibb
Conditions Basal Cell Carcinoma
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov